Cinclus Pharma Holding AB

https://www.cincluspharma.com

LinkedIn: https://www.linkedin.com/company/cincluspharma

Cinclus Pharma Holding AB is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. The beneficial safety and pharmacokinetic properties of linaprazan glurate have been documented in phase I studies. The Phase 2 study is ongoing in Europe and the US. Linaprazan glurate is a prodrug of the P-CAB linaprazan, developed originally by AstraZeneca. Linaprazan has been evaluated in 23 phase I, and two phase II studies in a total of approximately 2,500 subjects. Linaprazan glurate is being developed for treatment of severe Gastroesophageal reflux disease (GERD) and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs. Based on epidemiological data, the estimated size of this target population is 18.5 million and carries a Blockbuster potential (estimated sales exceeding USD 1 bn). The Company’s management team has extensive experience from the pharmaceutical industry with special focus on the GI pharmaceutical area with experience from AstraZeneca and Novartis. *

	Start	2014-01-01 established
	Group	Cinclus Pharma (Group)
	Industry	linaprazan glurate (X842)
	Industry 2	drug development
	Person	Ahlberg, Christer (Cinclus Pharma 202106– CEO before Sedana Medical Group)
	Person 2	Engström, Maria (Cinclus Pharma 202108– CFO before Sedana Medical Group + Cross Pharma AB)

	Region	Stockholm
	Country	Sweden
	Street	1 Kungsbron Plan 8, Trappa F
	City	11122 Stockholm
	Tel	+46-8-133310
		Address record changed: 2022-07-13

Basic data	Employees	n. a.

		* Document for »About Section«: Cinclus Pharma Holding AB. (5/20/22). "Press Release: Cinclus Pharma Has Carried Out a Successful Private Placement of approximately SEK 240m". Stockholm.

		Record changed: 2026-03-19

Picture Berlin Partner Voices Surjo Soekadar 650x200px

More documents for Cinclus Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)